Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Redbaron2211on Dec 03, 2021 8:21pm
182 Views
Post# 34197376

RE:Viacycte reports positive results from study

RE:Viacycte reports positive results from study
Nice to see Viacyce getting some exposure but what they have published so far isn't really anything to get excited about.  

After 6 months on immunosuppression some patients indicate positive C-peptide?  Was this found in the blood?  Because Viacyte did not include an absence of C-peptide as part of the Inclusion Criteria in their clinical trial I would question the validity especially when they don't mention any data.   "Results indicate positive C-peptide levels (a biomarker for insulin) as early as six months post-implant in some patients"
 
No details on HbA1c.  The only thing they mention is "13 percent more time in target glucose range" which is nothing substantial.  Honestly Viacyte seems to be doing what they do best burning cash and publishing vague results in scientific journals.    

 

<< Previous
Bullboard Posts
Next >>